Konstantinos Farsalinos, MD, MPH, is a physician and a research associate at the University of Patras and the University of West Attica in Greece. His field of expertise is Public Health. He has been conducting laboratory, clinical and epidemiological research on smoking, tobacco harm reduction and nicotine products as principal investigator since 2011. He authored the first systematic review on e-cigarette safety/risk profile, published in 2014. Additionally, he has performed research and published studies on heated tobacco products. His findings have been presented in major international scientific congresses and his studies were used in preparing the regulatory framework on e-cigarettes by the European Union in 2014. As of early 2024, he has published more than 100 studies and articles in international peer-reviewed scientific journals, mostly about smoking, tobacco harm reduction and alternative-to-smoking nicotine products. He has presented in more than 80 international conferences and he was the handling editor and author of a book titled "Analytical assessment of e-cigarettes", published by Elsevier in 2017. In November 2020, he was declared a Highly Cited Researcher 2019 by the Web of Science, a list of researchers (6200 scientists out of 9 million examined) with the highest impact in global science in 21 scientific fields in the past decade. During the COVID-19 pandemic, he has published 10 peer-reviewed articles and several pre-prints about COVID-19, including the association between smoking, nicotine and COVID-19.

Riccardo Polosa is the Founder of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR - University of Catania, Italy). Dr Polosa is Full Professor of Internal Medicine for the same University and Director of the Center for Smoking Prevention and Treatment at the University Hospital "Policlinico-V. Emanuele” of Catania. Dr. Polosa and the CoEHAR team of researchers conduct several high-profile clinical and behavioral research in the field of smoking-related diseases. According to a bibliometric analysis, Professor Polosa is considered the most productive scientist in the world in the field of electronic cigarette research.

Konstantinos Farsalinos, MD, MPH, is a physician and a research associate at the University of Patras and the University of West Attica in Greece. His field of expertise is Public Health. He has been conducting laboratory, clinical and epidemiological research on smoking, tobacco harm reduction and nicotine products as principal investigator since 2011. He authored the first systematic review on e-cigarette safety/risk profile, published in 2014. Additionally, he has performed research and published studies on heated tobacco products. His findings have been presented in major international scientific congresses and his studies were used in preparing the regulatory framework on e-cigarettes by the European Union in 2014. As of early 2024, he has published more than 100 studies and articles in international peer-reviewed scientific journals, mostly about smoking, tobacco harm reduction and alternative-to-smoking nicotine products. He has presented in more than 80 international conferences and he was the handling editor and author of a book titled "Analytical assessment of e-cigarettes", published by Elsevier in 2017. In November 2020, he was declared a Highly Cited Researcher 2019 by the Web of Science, a list of researchers (6200 scientists out of 9 million examined) with the highest impact in global science in 21 scientific fields in the past decade. During the COVID-19 pandemic, he has published 10 peer-reviewed articles and several pre-prints about COVID-19, including the association between smoking, nicotine and COVID-19.

Charles Hamshaw-Thomas worked with the two founding shareholders of E-Lites, the pioneering brand at the forefront of the UK vaping industry’s explosive early growth (2011-2015). Charlie led E-Lites’ external engagement – in London, Brussels and Washington DC – at the time when governments & regulators were first turning their attention to the nascent ‘new nicotine’ category. He also led E-Lites’ business development initiatives, which culminated in the sale of E-Lites to Japan Tobacco International in 2014. Since 2015, he has undertaken some consultancy roles to, and remained a close and enthusiastic observer of, the new industry. Charlie’s fervent wish is to see the industry truly realise its disruptive potential.

Professor Gerry Stimson is a leading advocate for tobacco harm reduction and an Emeritus Professor at Imperial College London. A public health social scientist, with over 50 years’ experience of research and advocacy, he was one of the founders of drugs harm reduction in the 1990s, helping to develop and evaluate harm reduction in the UK as a response to HIV/AIDS. Gerry has advised the UK Government, WHO, UNAIDS, UNODC, the World Bank and numerous governments around the world on issues relating to drugs, HIV infection and AIDS, and alcohol. He has also published over 220 scientific publications and several books. Currently, Gerry is advisor to Knowledge•Action•Change, and is involved in the FSFW-funded Global Tobacco Harm Reduction Initiative. He is also a co-founder of the Global Forum on Nicotine, which has been delivered by KAC Communications since 2014.

Peter Hajek is Professor of Clinical Psychology and Director of the Tobacco Dependence Research Unit at the Wolfson Institute of Preventive Medicine, Queen Mary University of London. His research is concerned primarily with understanding health behaviours, and developing and evaluating both behavioural and pharmacological treatments for dependent smokers and for people with weight problems. Professor Hajek is a member of a number of expert groups, advisory bodies and editorial boards, and has authored or co-authored over 350 publications.

Riccardo Polosa is the Founder of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR - University of Catania, Italy). Dr Polosa is Full Professor of Internal Medicine for the same University and Director of the Center for Smoking Prevention and Treatment at the University Hospital "Policlinico-V. Emanuele” of Catania. Dr. Polosa and the CoEHAR team of researchers conduct several high-profile clinical and behavioral research in the field of smoking-related diseases. According to a bibliometric analysis, Professor Polosa is considered the most productive scientist in the world in the field of electronic cigarette research.

Miroslaw Dworniczak, PhD - chemist, freelance science journalist, former scientist and lecturer at the Department of Chemistry, Adam Mickiewicz University (Poznan, Poland). Author (under the name "Stary Chemik" - "Old Chemist") of the first blog in Poland dealing with e-cigarettes and e-liquid chemistry and safety (http://starychemik.wordpress.com - in Polish) and the webpage for complete beginners (http://epapieros.edu.pl) including a manual for beginners in English (http://epapieros.edu.pl/manual-english/).

Miroslaw Dworniczak, PhD - chemist, freelance science journalist, former scientist and lecturer at the Department of Chemistry, Adam Mickiewicz University (Poznan, Poland). Author (under the name "Stary Chemik" - "Old Chemist") of the first blog in Poland dealing with e-cigarettes and e-liquid chemistry and safety (http://starychemik.wordpress.com - in Polish) and the webpage for complete beginners (http://epapieros.edu.pl) including a manual for beginners in English (http://epapieros.edu.pl/manual-english/).

Konstantinos Farsalinos, MD, MPH, is a physician and a research associate at the University of Patras and the University of West Attica in Greece. His field of expertise is Public Health. He has been conducting laboratory, clinical and epidemiological research on smoking, tobacco harm reduction and nicotine products as principal investigator since 2011. He authored the first systematic review on e-cigarette safety/risk profile, published in 2014. Additionally, he has performed research and published studies on heated tobacco products. His findings have been presented in major international scientific congresses and his studies were used in preparing the regulatory framework on e-cigarettes by the European Union in 2014. As of early 2024, he has published more than 100 studies and articles in international peer-reviewed scientific journals, mostly about smoking, tobacco harm reduction and alternative-to-smoking nicotine products. He has presented in more than 80 international conferences and he was the handling editor and author of a book titled "Analytical assessment of e-cigarettes", published by Elsevier in 2017. In November 2020, he was declared a Highly Cited Researcher 2019 by the Web of Science, a list of researchers (6200 scientists out of 9 million examined) with the highest impact in global science in 21 scientific fields in the past decade. During the COVID-19 pandemic, he has published 10 peer-reviewed articles and several pre-prints about COVID-19, including the association between smoking, nicotine and COVID-19.

Miroslaw Dworniczak, PhD - chemist, freelance science journalist, former scientist and lecturer at the Department of Chemistry, Adam Mickiewicz University (Poznan, Poland). Author (under the name "Stary Chemik" - "Old Chemist") of the first blog in Poland dealing with e-cigarettes and e-liquid chemistry and safety (http://starychemik.wordpress.com - in Polish) and the webpage for complete beginners (http://epapieros.edu.pl) including a manual for beginners in English (http://epapieros.edu.pl/manual-english/).

David Sweanor is an adjunct professor, Faculty of Law, and chair of the advisory board of the Centre for Health Law, Policy & Ethics at the University of Ottawa and has been actively involved in tobacco and health policy issues since the beginning of the 1980s. He has worked globally, and with numerous groups, including the International Union Against Cancer, World Health Organization, World Bank and the Pan American Health Organization and played a key role in achieving many global precedents in tobacco policy. He currently focuses much of his tobacco and nicotine related efforts on risk reduction strategies.